Temporomandibular Disorders

Back

Background

The joint

The normal human skull possesses 2 temporomandibular joints (TMJs) that connect the skull to the lower jaw bone (the mandible) so as to allow the mouth to open and close. The TMJ is a, gliding joint, formed by the condyle of the mandible and the squamous portion of the temporal bone. It is lined by fibrous connective tissue and enclosed within a fibrous capsule extending from the margins of the temporal portion of the joint superiorly to the neck of the mandible inferiorly. The articular surface of the temporal bone consists of a convex articular eminence anteriorly and a concave articular fossa posteriorly. The articular surface of the mandible consists of the top of the condyle. Articular surfaces of the mandible and temporal bone are separated by an articular disk, which divides the joint cavity into 2 small synovial cavities, the superior and inferior compartments. Gliding movements of the mandible (retrusion and protrusion) occur in the superior compartment. Hinge movements of the mandible (elevation and depression) occur in the inferior compartment. The joint is reinforced by multiple ligaments connecting the mandible to the sphenoid and temporal bones, and supported by the muscles of mastication. The joint is also surrounded on both sides by multiple important structures, which can be damaged during medical procedures.

The articular disk, also known as the meniscus, is a biconcave, fibrocartilaginous structure, which provides the gliding surface for the mandibular condyle, resulting in smooth joint movement. The meniscus has 3 parts—a thick anterior band, a thin intermediate zone, and a thick posterior band. With the mouth closed, the condyle is separated from the articular fossa of the temporal bone by the thick posterior band. When the mouth is open, the condyle is separated from the articular eminence of the temporal bone by the thin intermediate zone.

Movement of the TMJ is produced primarily by the muscles of mastication (masseter, medial and lateral pterygoids, and temporalis). All of these muscles arise from the first pharyngeal arch and are innervated by the third branch of the trigeminal nerve, the mandibular nerve. Their main action is to chew food by closing the mouth and moving the teeth from side to side. Parafunctional actions such as clenching and grinding can lead to pathology. Opening of the mouth is chiefly due to gravity, but can be performed against resistance primarily by the actions of the infrahyoid muscles and the platysma.

The syndrome

Temporomandibular disorder(s) (TMD), or temporomandibular joint syndrome, represent an array of pathologies affecting the TMJ and its surrounding structures. These disorders are linked in that they all can cause pain and limit the function of the TMJ. TMD is the most common cause of facial pain after toothache. In the past, many physicians called this condition TMJ disease or TMJ syndrome, but this nomenclature was replaced due to the growing body of scientific research regarding these disorders.TMD was previously known under the eponymous title of Costen syndrome, after Dr. James Costen, who elucidated many aspects of the syndrome as it relates to dental malocclusion. Today, a much more comprehensive view of this condition exists, and the term temporomandibular disorder (TMD) is the preferred term according to the American Academy of Orofacial Pain (AAOP) and most other groups who sponsor studies into its origins and treatment. Interestingly, the National Institute of Dental and Craniofacial Research (NIDCR) puts TMJ and TMD together and refers to them as temporomandibular joint disorder (TMJD). However, the term TMD is preferred and used in this article.

No unequivocal definition of the disease exists and 2 classification schemes are used. The AAOP classification divides TMD broadly into 2 syndromes:

Of note, these 2 types often coexist in one patient, making diagnosis and treatment more challenging. In addition, due to the anatomy of the mandible, dysfunction of one joint can impact the contralateral joint, and bilateral symptoms are common.

Myogenous TMD is more common. In its pure form, it lacks apparent destructive changes of the TMJ on radiograph and can be caused by multiple etiologies such as bruxism and daytime jaw clenching.

Arthrogenous TMD can be further specified as disk displacement disorder, chronic recurrent dislocations, degenerative joint disorders, systemic arthritic conditions, ankylosis, infections, and neoplasia. The most common is displacement disorder, which has two subtypes: anterior displacement with reduction and anterior displacement without reduction.

The Research Diagnostic Criteria for Temporomandibular Disorders (RDC/TMD) also exist.[1] The RDC/TMD criteria are composed of algorithms that aid in obtaining a diagnosis along 2 separate axes. The Axis I score provides what is considered the clinical diagnosis, and the Axis II score provides an assessment of mandibular function, psychological status, and level of TMD-related psychosocial disability. This discussion emphasizes the terminology and viewpoint of the AAOP approach. However, the authors are mindful of the important features of the RDC/TMD system. As is the case for most diseases and syndromes, the effect on the patient's life is a major feature of the problem and the psychological and psychosocial aspects are of great importance, and consideration of these factors necessitates a multidisciplinary approach in difficult cases. 

Pathophysiology

In myogenous temporomandibular disorder, the most common cause of the symptomatology (ie, pain, tenderness, and spasm of the mastication muscles) is muscular hyperactivity and dysfunction due to either parafunctional activities, or malocclusion of variable degree and duration. Psychological factors may also play a role. Studies have also linked regulatory pain pathways and local spread of pain signals within the cells of the spinal trigeminal nucleus to the severity, chronicity, and location of pain. 

In TMD of articular origin, disk displacement is the most common cause. Abnormal anterior displacement and interposition of the posterior band between the condyle and the eminence cause pain, pops, and crepitus. If the anteriorly displaced posterior band spontaneously returns to the normal position before the completion of jaw opening, it is called anterior displacement with reduction. It must be emphasized, however, that the presence of pops and clicks denoting anterior displacement with reduction does not necessarily denote pathology and studies of healthy populations have found these signs in a large percentage of individuals who did not later develop symptoms of TMD.

The sudden reduction of the posterior band causes the characteristic pop or click. If the posterior band remains anteriorly displaced at all times during jaw opening, it is called anterior displacement without reduction; full jaw opening may not be possible, and the distance between the incisors is usually less than 25mm. The jaw will usually deviate to the side of pathology. Inability to attain a jaw opening of more than 10 mm is known as closed lock. In TMD of articular origin, the spasm of the mastication muscle is secondary in nature. 

The other causes of arthrogenous TMD are diseases such as degenerative joint disease, rheumatoid arthritis, ankylosis, dislocations, infections, and neoplasia, the pathophysiology of which are self-explanatory. One study found that, in patients with chronic inflammatory connective tissue disease, the pain on mandibular movement and tenderness on posterior palpation of temporomandibular joints was related to the level of tumor necrosis factor alpha in the synovial fluid.

In a separate study, interleukin 1 receptor antagonist (IL-1ra) and soluble IL-1 receptor II (sIL-1RII) in the synovial fluid and blood plasma of patients with TMJ involvement of polyarthritis appeared to influence the TMJ inflammation.[2]

An important development may connect some of the psychosocial aspects of the disease to underlying neurobiology. This is the discovery that the likelihood of a patient being diagnosed with TMD is related to genetic variations in the gene coding for catecholamine-O-methyltransferase (COMT), a gene that relates in to some aspects of pain sensitivity.

Epidemiology

Frequency

United States

Temporomandibular disorder is a commonly seen condition in primary care and dentistry practice. According to some authorities, as many as 75% of the people in the United States population will at some time have some of the signs and symptoms of TMD; however, all of these individuals are not believed to have TMD. Between 5% and 10% of Americans may sufficiently fulfill the criteria to merit a diagnosis of TMD.

Race

In a recent study of young women aged 19-23 years, facial pain and jaw symptoms related to TMD were noted more frequently in Caucasians than in African Americans. Such symptoms also had an earlier onset in Caucasians.

Sex

Temporomandibular disorder primarily affects women with a male-to-female ratio of 1:4.

Age

Highest incidence is among young adults, especially women aged 20-40 years.

History

A comprehensive, chronological history and physical examination of the patient, including dental history and examination, is essential to diagnose the specific condition to decide further investigations, if any, and to provide specific treatment.   

Physical

See the list below:

Causes

See the list below:

In 2005, The National Institute of Dental and Craniofacial Research (NIDCR) began a 7-year clinical study, the Orofacial Pain: Prospective Evaluation and Risk Assessment (OPPERA) study, aimed at identifying risk factors for development of TMD. The study enrolls individuals who do not presently have TMD, and it will assess them by physical, psychological, and biochemical testing (including genetic screening) to determine the factors that lead to the development of TMD.

This study, with subsequent analysis of cohorts, has been published and has elucidated some factors appertaining to TMDs. There are genetic variants associated with TMDs, but no single nucleotide polymorphisms could be identified. Candidate gene associations with respect to nociception have been found and these include SCNA1 (voltage-gated sodium channel, type I, alpha subunit), ACE2 (angiotensin I-converting enzyme 2), MPDZ, (heat pain temporal summation with multiple PDZ domain protein), and APP (amyloid-beta precursor protein) Unfortunately, no causality has been firmly established.

Laboratory Studies

If a systemic illness is suspected to be the cause of temporomandibular disorder (TMD), lab work is required. CBC may be done if infection is suspected. Rheumatoid factor (RF), ESR, antinuclear antibody (ANA), and other specific antibodies are checked if rheumatoid arthritis, temporal arteritis, or a connective tissue disorder is suspected. Uric acid should be checked for gout. Pseudogout has also been reported in the temporomandibular joint (TMJ). Arthrocentesis is required to demonstrate specific crystals.

Imaging Studies

Conventional radiography is the most utilized imaging study. It is simple, evaluates bony structures, and in most cases is sufficient. It involves specific techniques and views such as modified Schuller views of each TMJ, both open mouth and closed mouth. Radiographic findings in TMJ depend on the etiology of TMD; in cases of rheumatoid arthritis and seronegative spondyloarthropathies, plain films show erosions, osteophytes, subchondral bony sclerosis, and condylar-glenoid fossa remodeling.

Dynamic high-resolution ultrasonography allows for visualization of the morphological elements and the functions of the TMJ, articular disk, mandibular condyle, and lateral pterygoid muscle. It is useful in the evaluation of internal derangements of the TMJ. One study found that the accuracy of prospective interpretation of high-resolution sonograms of internal derangement, disk displacement with reduction, and disk displacement without reduction was 95%, 92%, and 90%, respectively.[10]

CT scans can explore both bony structures and muscular soft tissues. Of interest, there is utility with cone beam computed tomography (CBCT). The patient is scanned with the mouth open and closed. Specifically, CBCT can aid in the diagnosis of osteoarthritis, rheumatoid arthritis, synovial chondromatosis, and neoplastic disorders.[11]

MRI should be used as the study of choice if an articular or meniscal pathology is suspected and an endoscopic or surgical procedure is contemplated, or in the case of traumatic TMD.

Other Tests

Quantitative analysis of occlusal strain and stress can be can be helpful by using photoplastic phenomenon of some polymers. Results of strain analysis can help harmonize static and kinematic occlusal patterns by detecting and eliminating prematurities and interferences. Stress analysis helps to understand the temporomandibular mechanical relationship.

Cephalometric analysis by the Delaire method allows for specific craniofacial morphotypic criteria to be defined.

Procedures

Diagnostic arthroscopy is an invasive diagnostic approach and should be used mainly in patients suffering from internal TMJ derangements recalcitrant to conservative measures. MRI is suggested to be obtained prior to arthroscopy.

Medical Care

Most temporomandibular disorders (TMDs) are self-limiting and do not get worse. Simple treatment, involving self-care practices, rehabilitation aimed at eliminating muscle spasms, and restoring correct coordination, is all that is required. Nonsteroidal anti-inflammatory analgesics (NSAIDs) should be used on a short-term, regular basis and not on an as needed basis.[12]

On the other hand, treatment of chronic TMD can be difficult and the condition is best managed by a team approach; the team consists of a primary care physician, a dentist, a physiotherapist, a psychologist, a pharmacologist, and in small number of cases, a surgeon. The different modalities include patient education and self-care practices, medication, physical therapy, splints, psychological counseling, relaxation techniques, biofeedback, hypnotherapy, acupuncture, and arthrocentesis.

Medications

Commonly used medications include NSAIDs, muscle relaxants, and tricyclic antidepressants. More recently, injections of botulinum toxin[13, 14] have been used, in some cases as an adjunct to arthrocentesis (see Arthrocentesis).

Ibuprofen and naproxen are commonly used NSAIDs. They work best when given on a regular basis for a period of 2-4 weeks with a gradual taper rather than a prn basis. Narcotics are reserved for patients with severe acute pain and should be used sparingly.

The commonly used muscle relaxants are diazepam, methocarbamol, and cyclobenzaprine. The lowest effective dose should be used initially. Adverse effects include sedation, depression and addiction.

Tricyclic antidepressants, in low doses, have been used effectively for a long time in chronic painful conditions. They act by inhibiting pain transmission and also may reduce nighttime bruxism. Amitriptyline and nortriptyline, in small doses, are the most common tricyclic antidepressants used for chronic painful conditions.

Botulinum toxin is used both as a single treatment[15] and in conjunction with arthrocentesis[16] (see Arthrocentesis). No controlled studies exist of the use of this medication in TMD. As noted in the article by Schwartz and Freund, care must be taken to isolate the muscle properly and inject appropriate doses. The authors know of no large-scale double-blind controlled trials on this subject, but some open-label studies have looked promising. A promising controlled study on facial pain associated with masticatory hyperactivity did show a significant benefit to botulinum toxin.[17] However, the patients were not diagnosed with TMD and it is not possible to tell which patients fulfilled diagnostic criteria for TMD.

Occlusal splints

These are known as nightguards, bruxism appliances, or orthotics. Various kinds of splints are available and can be classified into 2 groups—anterior repositioning splints and autorepositional splints. Physiologic basis of the pain relief provided by splints is not well understood. Factors such as alteration of occlusal relationships, redistribution of occlusal forces of bite, and alteration of structural relationship and forces in the temporomandibular joint (TMJ) seem to play some role.

Autorepositional splints, also known as muscle splints, are used most frequently. Some sort of pain relief is seen in as many as 70-90% of patients using splints. In acute cases the splint may be worn 24 hours a day for several months and as the condition permits, worn at night only.

Hyaluronic acid injections

There have been some recent musings in the literature about the effectiveness of this treatment for TMD. A meta-analysis was published that drew inconclusive results regarding the effectiveness of this treatment, citing that it seemed to be comparable to treatment with occlusal splints. This study did comment on the fact that there was a response compared to placebo, but more data needs to be accumulated and examined prior to drawing any conclusions concerning the effectiveness of hyaluronic acid injections for the treatment of TMD.[18] Another recent study examined the effectiveness of hyaluronic acid injections in various forms of osteoarthritis and they too came to the conclusion that its effectiveness is questionable and is not superior to intra-articular injections of corticosteroids.[19]

Surgical Care

The treatment of chronic TMD is difficult and it may appropriate during the course of the disease to discuss surgical treatment options.

Consultations

See the list below:

Medication Summary

Medications are helpful only for symptomatic relief and should be used only for short periods. NSAIDs, whenever used, should be administered on a short-term regular basis and not prn.

Ibuprofen (Motrin, Ibuprin)

Clinical Context:  DOC for mild to moderately severe pain; inhibits inflammatory reactions and pain by decreasing prostaglandin synthesis.

Naproxen (Aleve, Naprelan, Naprosyn)

Clinical Context:  For relief of mild to moderately severe pain; inhibits inflammatory reactions and pain by decreasing activity of cyclooxygenase, which is responsible for prostaglandin synthesis.

Class Summary

These agents have analgesic, anti-inflammatory, and antipyretic activities. Their mechanism of action is not known, but they may inhibit cyclooxygenase activity and prostaglandin synthesis. Other mechanisms may exist as well, such as inhibition of leukotriene synthesis, lysosomal enzyme release, lipoxygenase activity, neutrophil aggregation, and various cell-membrane functions.

Methocarbamol (Robaxin)

Clinical Context:  Reduces nerve impulse transmission from spinal cord to skeletal muscle.

Cyclobenzaprine (Flexeril)

Clinical Context:  Skeletal muscle relaxant that acts centrally and reduces motor activity of tonic somatic origins, influencing both alpha and gamma motor neurons. Structurally related to tricyclic antidepressants; therefore, has some of same limitations.

Class Summary

These agents relieve muscle spasms.

Diazepam (Valium, Diastat)

Clinical Context:  Depresses all levels of CNS (eg, limbic and reticular formation), possibly by increasing activity of GABA.

Individualize dosage and increase cautiously to avoid adverse effects.

Class Summary

By binding to specific receptor sites, these agents appear to potentiate the effects of GABA and facilitate inhibitory GABA neurotransmission and other inhibitory transmitters.

Botulinum toxin type A (BOTOX)

Clinical Context:  One of several toxins produced by Clostridium botulinum. Blocks neuromuscular transmission through a 3-step process, as follows: (1) blockade of neuromuscular transmission; botulinum toxin type A (BTA) binds to the motor nerve terminal. The binding domain of the type A molecule appears to be the heavy chain, which is selective for cholinergic nerve terminals. (2) BTA is internalized via receptor-mediated endocytosis, a process in which the plasma membrane of the nerve cell invaginates around the toxin-receptor complex, forming a toxin-containing vesicle inside the nerve terminal. After internalization, the light chain of the toxin molecule, which has been demonstrated to contain the transmission-blocking domain, is released into the cytoplasm of the nerve terminal. (3) BTA blocks acetylcholine release by cleaving SNAP-25, a cytoplasmic protein that is located on the cell membrane and that is required for the release of this transmitter.

The affected terminals are inhibited from stimulating muscle contraction. Toxin does not affect synthesis or storage of acetylcholine or conduction of electrical signals along the nerve fiber. Typically, a 24-72 h delay between administration of toxin and onset of clinical effects exists, which terminate in 2-6 mo. This purified neurotoxin complex is a vacuum-dried form of purified BTA, which contains 5 ng of neurotoxin complex protein per 100 U.

Treats excessive, abnormal contractions associated with blepharospasm. BTA has to be reconstituted with 2 mL of 0.9% sodium chloride diluent. With this solution, each 0.1 mL results in 5 U dose. Patient should receive 5-10 injections per visit. Must be reconstituted from vacuum-dried toxin into 0.9% sterile saline without preservative using manufacturer's instructions to provide injection volume of 0.1 mL; must be used within 4 h of storage in refrigerator at 2-8°C. Preconstituted dry powder must be stored in freezer at < 5°C.

Reexamine patient 7-14 d after initial dose to assess for response. Increase doses 2-fold over previous one for patients experiencing incomplete paralysis of target muscle. Do not exceed 25 U when giving it as single injection or 200 U as cumulative dose in 30-d period. For the purpose of TMD treatment, studies are limited and the medication is not approved. The dosing approach to specific muscles, such as they are known, is given in the article by Schwartz and Freund.

Class Summary

Used experimentally.

Prognosis

Most cases of temporomandibular disorder (TMD) respond to simple treatment and the prognosis is good. Symptoms usually remit with simple care. In cases of secondary involvement of temporomandibular joint (TMJ), the prognosis depends on the primary disease. A second opinion should be obtained in cases in which irreversible treatment is being considered.

Patient Education

See the list below:

Author

Joseph Rios, MD, Assistant Professor, Department of Medical Education, University of Central Florida College of Medicine

Disclosure: Nothing to disclose.

Coauthor(s)

Stephen A Berman, MD, PhD, MBA, Professor of Neurology, University of Central Florida College of Medicine

Disclosure: Nothing to disclose.

Specialty Editors

Francisco Talavera, PharmD, PhD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Chief Editor

Robert A Egan, MD, NW Neuro-Ophthalmology

Disclosure: Received honoraria from Biogen Idec and Genentech for participation on Advisory Boards.

Additional Contributors

Charles F Guardia, III, MD, Instructor in Neurology, Department of Neurology, Dartmouth Hitchcock Medical Center, Geisel School of Medicine at Dartmouth

Disclosure: Nothing to disclose.

Michael J Schneck, MD, MBA, Vice Chair and Professor, Departments of Neurology and Neurosurgery, Loyola University, Chicago Stritch School of Medicine; Associate Director, Stroke Program, Director, Neurology Intensive Care Program, Medical Director, Neurosciences ICU, Loyola University Medical Center

Disclosure: Received honoraria from Boehringer-Ingelheim for speaking and teaching; Received honoraria from Sanofi/BMS for speaking and teaching; Received honoraria from Pfizer for speaking and teaching; Received honoraria from UCB Pharma for speaking and teaching; Received consulting fee from Talecris for other; Received grant/research funds from NMT Medical for independent contractor; Received grant/research funds from NIH for independent contractor; Received grant/research funds from Sanofi for independe.

Acknowledgements

The authors and editors of Medscape Reference gratefully acknowledge the contributions of previous authors Arun Chaudhary, MD; Jeffrey Appelbaum, DO; and Jennifer Ault, DO, DPT to the development and writing of this article.

References

  1. Schiffman E, Ohrbach R. Executive summary of the Diagnostic Criteria for Temporomandibular Disorders for clinical and research applications. J Am Dent Assoc. 2016 Jun. 147 (6):438-45. [View Abstract]
  2. Alstergren P, Benavente C, Kopp S. Interleukin-1beta, interleukin-1 receptor antagonist, and interleukin-1 soluble receptor II in temporomandibular joint synovial fluid from patients with chronic polyarthritides. J Oral Maxillofac Surg. 2003 Oct. 61(10):1171-8. [View Abstract]
  3. Perri R, Huta V, Pinchuk L, Pinchuk C, Ostry DJ, Lund JP. Initial Investigation of the relation between extended computer use and temporomandibular joint disorders. J Can Dent Assoc. 2008 Sep. 74(7):643. [View Abstract]
  4. Rossetti LM, Pereira de Araujo Cdos R, Rossetti PH, Conti PC. Association between rhythmic masticatory muscle activity during sleep and masticatory myofascial pain: a polysomnographic study. J Orofac Pain. 2008 Summer. 22(3):190-200. [View Abstract]
  5. Sanders AE, Maixner W, Nackley AG, Diatchenko L, By K, Miller VE, et al. Excess risk of temporomandibular disorder associated with cigarette smoking in young adults. J Pain. 2012 Jan. 13(1):21-31. [View Abstract]
  6. Gonçalves DA, Camparis CM, Speciali JG, Franco AL, Castanharo SM, Bigal ME. Temporomandibular disorders are differentially associated with headache diagnoses: a controlled study. Clin J Pain. 2011 Sep. 27(7):611-5. [View Abstract]
  7. Graff-Radford SB, Abbott JJ. Temporomandibular Disorders and Headache. Oral Maxillofac Surg Clin North Am. 2016 Aug. 28 (3):335-49. [View Abstract]
  8. Smith SB, Mir E, Bair E, Slade GD, Dubner R, Fillingim RB. Genetic Variants Associated With Development of TMD and Its Intermediate Phenotypes: The Genetic Architecture of TMD in the OPPERA Prospective Cohort Study. J Pain. 2013 Dec. 14(12 Suppl):T91-T101.e3. [View Abstract]
  9. Porto De Toledo I, Stefani FM, Porporatti AL, Mezzomo LA, Peres MA, Flores-Mir C, et al. Prevalence of otologic signs and symptoms in adult patients with temporomandibular disorders: a systematic review and meta-analysis. Clin Oral Investig. 2016 Aug 10. [View Abstract]
  10. Emshoff R, Jank S, Bertram S, Rudisch A, Bodner G. Disk displacement of the temporomandibular joint: sonography versus MR imaging. AJR Am J Roentgenol. 2002 Jun. 178(6):1557-62. [View Abstract]
  11. Tsiklakis K. Cone beam computed tomographic findings in temporomandibular joint disorders. Alpha Omegan. 2010 Jun. 103(2):68-78. [View Abstract]
  12. Gauer RL, Semidey MJ. Diagnosis and treatment of temporomandibular disorders. Am Fam Physician. 2015 Mar 15. 91 (6):378-86. [View Abstract]
  13. Borodic GE, Acquadro MA. The use of botulinum toxin for the treatment of chronic facial pain. J Pain. 2002 Feb. 3(1):21-7. [View Abstract]
  14. Kurtoglu C, Gur OH, Kurkcu M, Sertdemir Y, Guler-Uysal F, Uysal H. Effect of botulinum toxin-A in myofascial pain patients with or without functional disc displacement. J Oral Maxillofac Surg. 2008 Aug. 66(8):1644-51. [View Abstract]
  15. Schwartz M, Freund B. Treatment of temporomandibular disorders with botulinum toxin. Clin J Pain. 2002 Nov-Dec. 18(6 Suppl):S198-203. [View Abstract]
  16. Freund BJ, Schwartz M. Intramuscular injection of botulinum toxin as an adjunct to arthrocentesis of the temporomandibular joint: preliminary observations. Br J Oral Maxillofac Surg. 2003 Oct. 41(5):351-2. [View Abstract]
  17. von Lindern JJ, Niederhagen B, Berge S. Type A botulinum toxin in the treatment of chronic facial pain associated with masticatory hyperactivity. J Oral Maxillofac Surg. 2003 Jul. 61(7):774-8. [View Abstract]
  18. Manfredini D, Piccotti F, Guarda-Nardini L. Hyaluronic acid in the treatment of TMJ disorders: a systematic review of the literature. Cranio. 2010 Jul. 28(3):166-76. [View Abstract]
  19. Colen S, Haverkamp D, Mulier M, van den Bekerom MP. Hyaluronic acid for the treatment of osteoarthritis in all joints except the knee: what is the current evidence?. BioDrugs. 2012. 26:101-12. [View Abstract]
  20. Rigon M, Pereira LM, Bortoluzzi MC, et al. Arthroscopy for temporomandibular disorders. Cochrane Database Syst Rev. 2011 May 11. 5:CD006385. [View Abstract]
  21. Mercuri LG, Ali FA, Woolson R. Outcomes of total alloplastic replacement with periarticular autogenous fat grafting for management of reankylosis of the temporomandibular joint. J Oral Maxillofac Surg. 2008 Sep. 66(9):1794-803. [View Abstract]
  22. Al-Jabrah OA, Al-Shumailan YR. Prevalence of temporomandibular disorder signs in patients with complete versus partial dentures. Clin Oral Investig. 2006 Sep. 10(3):167-73. [View Abstract]
  23. Andreu Y, Galdon MJ, Dura E, Ferrando M, Pascual J, Turk DC, et al. An examination of the psychometric structure of the Multidimensional Pain Inventory in temporomandibular disorder patients: a confirmatory factor analysis. Head Face Med. 2006 Dec 14. 2:48. [View Abstract]
  24. Arcan M, Zandman F. A method for in vivo quantitative occlusal strain and stress analysis. J Biomech. 1984. 17(2):67-79. [View Abstract]
  25. Baggi L, Rubino IA, Zanna V, Martignoni M. Personality disorders and regulative styles of patients with temporo-mandibular joint pain dysfunction syndrome. Percept Mot Skills. 1995 Feb. 80(1):267-73. [View Abstract]
  26. Baltali E, Keller EE. Surgical management of advanced osteoarthritis of the temporomandibular joint with metal fossa-eminence hemijoint replacement: 10-year retrospective study. J Oral Maxillofac Surg. 2008 Sep. 66(9):1847-55. [View Abstract]
  27. Barkin S, Weinberg S. Internal derangements of the temporomandibular joint: the role of arthroscopic surgery and arthrocentesis. J Can Dent Assoc. 2000 Apr. 66(4):199-203. [View Abstract]
  28. Bedrune B, Jammet P, Chossegros C. [Temporomandibular joint pain-dysfunction syndrome after whiplash injury. Medico-legal problems in common law]. Rev Stomatol Chir Maxillofac. 1992. 93(6):408-13. [View Abstract]
  29. Blanchard P, Scheffer P, Lerondeau JC. [Craniofacial architecture and temporomandibular joint pain-dysfunction syndrome. The possibility of orthodontic treatment]. Rev Stomatol Chir Maxillofac. 1990. 91 Suppl 1:105-7. [View Abstract]
  30. Camparis CM, Formigoni G, Teixeira MJ, Bittencourt LR, Tufik S, de Siqueira JT. Sleep bruxism and temporomandibular disorder: Clinical and polysomnographic evaluation. Arch Oral Biol. 2006 Sep. 51(9):721-8. [View Abstract]
  31. Cascone P, Spallaccia F, Rivaroli A. [Arthrocentesis of the temporomandibular joint. Long-term results]. Minerva Stomatol. 1998 Apr. 47(4):149-57. [View Abstract]
  32. Chossegros C, Cheynet F, Blanc JL. [Diagnostic temporo-mandibular arthroscopy. Principle lesions, apropos of 50 case reports]. Rev Stomatol Chir Maxillofac. 1991. 92(3):141-8. [View Abstract]
  33. Costen JB. A syndrome of ear and sinus symptoms dependent upon disturbed function of the temporomandibular joint. 1934. Ann Otol Rhinol Laryngol. 1997 Oct. 106(10 Pt 1):805-19. [View Abstract]
  34. Cox KW. Temporomandibular disorder and new aural symptoms. Arch Otolaryngol Head Neck Surg. 2008 Apr. 134(4):389-93. [View Abstract]
  35. Cros P, Freidel M, Borie J. [15 years of treatment of temporomandibular joint algo-dysfunctional syndromes]. Rev Stomatol Chir Maxillofac. 1989. 90(6):409-14. [View Abstract]
  36. da Cunha SC, Nogueira RV, Duarte AP, Vasconcelos BC, Almeida Rde A. Analysis of helkimo and craniomandibular indexes for temporomandibular disorder diagnosis on rheumatoid arthritis patients. Braz J Otorhinolaryngol. 2007 Jan-Feb. 73(1):19-26. [View Abstract]
  37. de Filippis C, Osti L, Osti R. [Algodystrophic syndrome of the temporo-mandibular joint: a clinical experience]. Acta Otorhinolaryngol Ital. 1998 Apr. 18(2):111-5. [View Abstract]
  38. Diatchenko L, Slade GD, Nackley AG. Genetic basis for individual variations in pain perception and the development of a chronic pain condition. Hum Mol Genet. 2005 Jan 1. 14(1):135-43. [View Abstract]
  39. Esposito CJ, Panucci PJ, Farman AG. Associations in 425 patients having temporomandibular disorders. J Ky Med Assoc. 2000 May. 98(5):213-5. [View Abstract]
  40. Ey-Chmielewska H. [An attempt to use ultrasonic technique for confirming the diagnosis, planning and observation of long-term treatment results of painful temporo-mandibular joint dysfunction]. Ann Acad Med Stetin. 1998. 44:223-36. [View Abstract]
  41. Fassauer H, Bethmann W, Begemeier I. [Diseases of the temporomandibular joint--a clinical statistical study]. Stomatol DDR. 1977 Jun. 27(6):359-67. [View Abstract]
  42. Ferrari R, Schrader H, Obelieniene D. Prevalence of temporomandibular disorders associated with whiplash injury in Lithuania. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1999 Jun. 87(6):653-7. [View Abstract]
  43. Gallucci M, Bozzao A, Splendiani A. [Magnetic resonance in condylo-meniscal incoordination pathology of the temporomandibular joint. Indications, diagnostic accuracy and optimization of study techniques]. Radiol Med (Torino). 1991 Apr. 81(4):404-11. [View Abstract]
  44. Gatchel RJ, Stowell AW, Buschang P. The relationships among depression, pain, and masticatory functioning in temporomandibular disorder patients. J Orofac Pain. 2006 Fall. 20(4):288-96. [View Abstract]
  45. Gatchel RJ, Stowell AW, Wildenstein L, Riggs R, Ellis E 3rd. Efficacy of an early intervention for patients with acute temporomandibular disorder-related pain: a one-year outcome study. J Am Dent Assoc. 2006 Mar. 137(3):339-47. [View Abstract]
  46. Glaros AG. Temporomandibular disorders and facial pain: a psychophysiological perspective. Appl Psychophysiol Biofeedback. 2008 Sep. 33(3):161-71. [View Abstract]
  47. Goddard G. Controversies in TMD. J Calif Dent Assoc. 1998 Nov. 26(11):827-32. [View Abstract]
  48. Granat O, Pharaboz C, Gerber S. [The diagnostic importance of different imaging technics in temporomandibular joint dysfunction]. Actual Odontostomatol (Paris). 1989 Sep. 43(167):417-32. [View Abstract]
  49. Huang GJ, Rue TC. Third-molar extraction as a risk factor for temporomandibular disorder. J Am Dent Assoc. 2006 Nov. 137(11):1547-54. [View Abstract]
  50. Irving J, Wood GD, Hackett AF. Does temporomandibular disorder pain dysfunction syndrome affect dietary intake?. Dent Update. 1999 Nov. 26(9):405-7. [View Abstract]
  51. Janson M, Janson G, Sant'Ana E, Nakamura A, de Freitas MR. Segmental LeFort I osteotomy for treatment of a Class III malocclusion with temporomandibular disorder. J Appl Oral Sci. 2008 Jul-Aug. 16(4):302-9. [View Abstract]
  52. Jedel E, Carlsson J, Stener-Victorin E. Health-related quality of life in child patients with temporomandibular disorder pain. Eur J Pain. 2007 Jul. 11(5):557-63. [View Abstract]
  53. Losapio PL, Amaddeo P. [A case of true congenital temporo-mandibular ankylosis]. Minerva Stomatol. 1989 May. 38(5):505-8. [View Abstract]
  54. Medlicott MS, Harris SR. A systematic review of the effectiveness of exercise, manual therapy, electrotherapy, relaxation training, and biofeedback in the management of temporomandibular disorder. Phys Ther. 2006 Jul. 86(7):955-73. [View Abstract]
  55. Meng QG, Long X. A hypothetical biological synovial fluid for treatment of temporomandibular joint disease. Med Hypotheses. 2008. 70(4):835-7. [View Abstract]
  56. Modica R, Mongini F. [Limitations in the opening of the mouth of an arthrogenic nature]. Minerva Stomatol. 1975 Jul-Dec. 24(4):163-76. [View Abstract]
  57. Ojima K, Watanabe N, Narita N, Narita M. Temporomandibular disorder is associated with a serotonin transporter gene polymorphism in the Japanese population. Biopsychosoc Med. 2007 Jan 10. 1:3. [View Abstract]
  58. Okeson JP, de Kanter RJ. Temporomandibular disorders in the medical practice. J Fam Pract. 1996 Oct. 43(4):347-56. [View Abstract]
  59. Ortega AO, Guimaraes AS, Ciamponi AL, Marie SK. Frequency of temporomandibular disorder signs in individuals with cerebral palsy. J Oral Rehabil. 2008 Mar. 35(3):191-5. [View Abstract]
  60. Plesh O, Crawford PB, Gansky SA. Chronic pain in a biracial population of young women. Pain. 2002 Oct. 99(3):515-23. [View Abstract]
  61. Reissmann DR, John MT, Schierz O, Wassell RW. Functional and psychosocial impact related to specific temporomandibular disorder diagnoses. J Dent. 2007 Aug. 35(8):643-50. [View Abstract]
  62. Reissmann DR, John MT, Wassell RW, Hinz A. Psychosocial profiles of diagnostic subgroups of temporomandibular disorder patients. Eur J Oral Sci. 2008 Jun. 116(3):237-44. [View Abstract]
  63. Sasaki J, Ariji Y, Sakuma S, et al. Ultrasonography as a tool for evaluating treatment of the masseter muscle in temporomandibular disorder patients with myofascial pain. Oral Radiol. 2006. 22:52-7.
  64. Scutellari PN, Orzincolo C, Ceruti S. [The temporo-mandibular joint in pathologic conditions: rheumatoid arthritis and seronegative spondyloarthritis]. Radiol Med (Torino). 1993 Oct. 86(4):456-66. [View Abstract]
  65. Seligman DA, Pullinger AG. Dental attrition models predicting temporomandibular joint disease or masticatory muscle pain versus asymptomatic controls. J Oral Rehabil. 2006 Nov. 33(11):789-99. [View Abstract]
  66. Soudant J, Lamas G. [Surgical treatment of temporomandibular joint dysfunctions by Myrhaug's technic. Apropos 60 interventions]. Rev Stomatol Chir Maxillofac. 1987. 88(3):208-12. [View Abstract]
  67. Speculand B, Goss AN, Hughes A. Temporo-mandibular joint dysfunction: pain and illness behaviour. Pain. 1983 Oct. 17(2):139-50. [View Abstract]
  68. Stam HJ, McGrath PA, Brooke RI. The effects of a cognitive-behavioral treatment program on temporo-mandibular pain and dysfunction syndrome. Psychosom Med. 1984 Nov-Dec. 46(6):534-45. [View Abstract]
  69. Tosato Jde P, Caria PH. Electromyographic activity assessment of individuals with and without temporomandibular disorder symptoms. J Appl Oral Sci. 2007 Apr. 15(2):152-5. [View Abstract]
  70. Truelove E, Huggins KH, Mancl L, Dworkin SF. The efficacy of traditional, low-cost and nonsplint therapies for temporomandibular disorder: a randomized controlled trial. J Am Dent Assoc. 2006 Aug. 137(8):1099-107; quiz 1169. [View Abstract]
  71. Tschopp K, Bachmann R. [Temporomandibular myoarthropathy syndrome--a frequent cause of facial pain]. Schweiz Rundsch Med Prax. 1992 Apr 7. 81(15):468-72. [View Abstract]
  72. Tsuyama M, Kondoh T, Seto K. Complications of temporomandibular joint arthroscopy: a retrospective analysis of 301 lysis and lavage procedures performed using the triangulation technique. J Oral Maxillofac Surg. 2000 May. 58(5):500-5; discussion 505-6. [View Abstract]
  73. Turner JA, Mancl L, Aaron LA. Short- and long-term efficacy of brief cognitive-behavioral therapy for patients with chronic temporomandibular disorder pain: a randomized, controlled trial. Pain. 2006 Apr. 121(3):181-94. [View Abstract]
  74. Uhac I, Kovac Z, Muhvic-Urek M, Kovacevic D, Franciskovic T, Simunovic-Soskic M. The prevalence of temporomandibular disorders in war veterans with post-traumatic stress disorder. Mil Med. 2006 Nov. 171(11):1147-9. [View Abstract]
  75. Valle-Corotti K, Pinzan A, Valle CV, Nahás AC, Corotti MV. Assessment of temporomandibular disorder and occlusion in treated class III malocclusion patients. J Appl Oral Sci. 2007 Apr. 15(2):110-4. [View Abstract]
  76. Wadhwa S, Kapila S. TMJ disorders: future innovations in diagnostics and therapeutics. J Dent Educ. 2008 Aug. 72(8):930-47. [View Abstract]
  77. Wakita T, Mogi M, Kurita K, Kuzushima M, Togari A. Increase in RANKL: OPG ratio in synovia of patients with temporomandibular joint disorder. J Dent Res. 2006 Jul. 85(7):627-32. [View Abstract]
  78. Zajko J, Satko I, Hirjak D. [Treatment of dysfunction of the temporomandibular joint by an occlusion splint]. Prakt Zubn Lek. 1990 Jun. 38(5):151-4. [View Abstract]